Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 7Sarcoma 6Prostatic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 3Liposarcoma, Myxoid 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Sarcoma, Synovial 2Neurofibrosarcoma 2Melanoma 2Liposarcoma 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Fibrosarcoma 2Carcinoma, Intraductal, Noninfiltrating 2Advanced Refractory Solid Tumors 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thymoma 1Small Cell Lung Cancer Limited Stage 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Myosarcoma 1Lymphatic Metastasis 1Lymphangiosarcoma 1Locally Recurrent Rectal Cancer 1

Interventions

Gemcitabine 295Fluorouracil 82Oxaliplatin 81130-nm albumin-bound paclitaxel 68Capecitabine 60Leucovorin 56Albumin-Bound Paclitaxel 54Radiotherapy 51Irinotecan 44Taxes 37Cisplatin 36Erlotinib Hydrochloride 34Radiosurgery 33pembrolizumab 29Docetaxel 27S 1 (combination) 26Bevacizumab 23folfirinox 22Nivolumab 21Magnetic Resonance Spectroscopy 17Cyclophosphamide 17Cetuximab 17irinotecan sucrosofate 16Radiation 16Drug Therapy 15Surgical Procedures, Operative 14Specimen Handling 11Biopsy 11durvalumab 10Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pancreatic Neoplasms × Radiation Dose Hypofractionation × Clear all
NCT06435260 2025-06-26

Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer

Hebei Medical University Fourth Hospital

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡